Register now and get 10% first deposit bonus.Get bonus! 
Johnston & Johnson's stock is a blue-chip security. This company has established itself as a competitive and reliable healthcare corporation. It also pays dividends, while increasing distributions to shareholders over several decades.
Johnson & Johnson is an American multinational corporation founded in 1886 that manufactures medical devices, pharmaceuticals, and consumer products. It was founded by three brothers: Robert, James, and Edward Mead Johnson. Now the holding company has more than 250 subsidiaries.
Johnson & Johnson stock is listed on the stock exchange under the ticker symbol NYSE: JNJ. This asset is also part of the Dow Jones Global Titans 50 Index. The corporation's IPO was held in 1944. At that time, Johnson & Johnson shares were trading at $37.5. In October 2022, their value was at $170. The company's market capitalization is about $450 billion.
Johnson is a diversified healthcare company that manufactures and sells a wide range of consumer and healthcare products. The company's products include over-the-counter medications, wound care products, and contact lenses. Johnson also owns several pharmaceutical companies, including Janssen Pharmaceuticals and McNeil Consumer Healthcare. The company has operations in more than 60 countries and employs about 130,000 people worldwide.
Johnson's consumer products include children's products, over-the-counter medications, skin care products, and first aid products. The company's pharmaceutical products include treatments for cancer, HIV/AIDS, Alzheimer's, and diabetes. Johnson is a diversified company with a long history of success. Its products impact the lives of people around the world every day and its strong brands are trusted by consumers. The company is committed to meeting the needs of patients and customers with innovative products and services.
Johnson & Johnson shares through October 2022 have fallen about 6% since the beginning of the year. That's a fairly small decline in quotations, given the collapse of the stock market in 2022. Now analysts expect the Johnson & Johnson stock price to stabilize. The favorable moment for the growth of JNJ quotes is the recovery of the healthcare industry in the second half of 2022.
JNJ management has approved plans to buy back $5 billion worth of Johnson & Johnson stock. As of July 2022, there were more than 2.6 billion common securities in circulation on the stock market. The buyback program has no time limit and can be suspended at the discretion of management.
Johnson & Johnson's financial performance in the third quarter of 2022 exceeded the expectations of investors and analysts. The corporation's revenues rose nearly 2% to $23.79 billion. In the U.S., J & J sales rose 4%. In the international segment, the company's revenues decreased by 0.3% in U.S. dollars. This was due to the appreciation of the U.S. currency. At the same time, the corporation's revenue in local currency increased by 12%.
Johnson & Johnson's adjusted earnings per share were $2.55 per security. That figure was above what many investors expected, although it was down 2% from the same period in 2021. In 2023, investors expect an even greater increase in the value of JNJ stock. This is because J & J management expects strong operating earnings to offset the weakness of the foreign currency against the dollar.
At the time of the Johnson & Johnson stock price forecast, the value of this asset was $170. According to technical analysis, quotes will fluctuate between $178 and $200 in 2023. By 2025, this asset has the potential to grow to $300 or higher. For 2030, our analysts forecast the growth of the share price above $600. The pharma company's stable earnings and ability to stay afloat even during crises plays into its hands.
To authorize on the website and create a personal account, fill out the form, indicating your name, phone number, email address.
After registration, provide an identity document to verify your age and place of residence.
To start trading real money, the initial deposit can be made in any available way.
You can open/close deals on your own under the guidance of an experienced analyst or copy them from other traders.
No trading experience? Not a problem! With social trading, you can copy the trades of the best DotBig traders. Follow the rating and make a profit.
Start trading
